{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-066276","form_type":"8-K","ticker":"SGHT","cik":"0001531177","company_name":"Sight Sciences, Inc.","filed_at":"2024-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.869665+00:00","generated_at":"2026-06-01T07:23:12.662155+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sight Sciences: Draft Medicare LCDs propose no coverage restrictions for OMNI and SION","bullets":["Five MACs published draft LCDs on MIGS not proposing specific coverage criteria for OMNI (canaloplasty+trabeculotomy) or SION (goniotomy).","These procedures would remain eligible for Medicare in states covering 62% of Sight Sciences' 2023 Surgical Glaucoma revenue.","Draft LCDs propose non-coverage when an aqueous shunt/stent is performed with a MIGS procedure in the same eye at same time.","45-day comment period; finalization within 365 days. Company plans to engage with MACs, CMS, and clinical societies."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-066276","json":"https://secwatch.observer/filing/0000950170-24-066276.json","markdown":"https://secwatch.observer/filing/0000950170-24-066276.md","text":"https://secwatch.observer/filing/0000950170-24-066276.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1531177/000095017024066276/0000950170-24-066276-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1531177/000095017024066276/sght-20240530.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T07:23:12.662155+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}